What the Advisers Decided
A federal advisory panel voted 9 to 3 on July 29 that the available evidence does not support the effectiveness of deramiocel for treating the heart muscle disease that develops in Duchenne muscular dystrophy.
The vote came from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee, which reviewed Capricor Therapeutics' application for the cell therapy. The panel was asked a single question: whether one trial provided substantial evidence that the treatment works against Duchenne cardiomyopathy.
For families, the immediate practical point is narrow. The vote does not remove anything from a child's current care, because no therapy is presently approved specifically for the cardiac component of Duchenne. Nothing that a cardiologist prescribes changes today because of this vote.
The second practical point is that the vote is not the decision. Advisory committee recommendations are advisory only. The Muscular Dystrophy Association noted that the vote is non-binding and that the agency is expected to rule before its August 22 target date.
Why the August 22 Date Still Matters
Heart muscle deterioration is the leading cause of death in Duchenne muscular dystrophy, a genetic condition that affects roughly 15,000 people in the United States and primarily affects boys. As respiratory care has improved over the past two decades, cardiac disease has become the dominant threat.
That is why the calendar carries weight for households that have been following this application. Between now and August 22, the FDA completes its own review. The agency generally follows its advisers, though it is not required to, and it has departed from panel recommendations before.
Families who want a community explanation of what follows an advisory committee meeting have a scheduled touchpoint. Parent Project Muscular Dystrophy and the Muscular Dystrophy Association have pointed families toward a town hall on August 4 at 1 p.m. Eastern addressing what happens after an advisory committee hearing.
Anyone planning around that date should treat it as an information session rather than a source of new regulatory facts. The FDA does not preview its decisions at advocacy events.
What Changed Since MedicalDaily's Earlier Report
MedicalDaily previously reported on the advisory committee meeting as it convened, describing the single voting question and the agency's written assessment of the trial.
At that point, the outcome was unknown. What is different now is that the panel has voted, the margin was lopsided, and the discussion revealed where the disagreement actually sits. The panel also discussed a second measure, upper limb function, which was not the subject of the formal vote. Some advisers considered that evidence somewhat stronger, though still unproven. Christopher Coffey, a biostatistics professor at the University of Iowa's College of Public Health, described those data as "a little more favorable."
That distinction matters because the application before the agency concerns cardiomyopathy. A more favorable impression of a different measure does not automatically translate into approval for the indication under review.
The Statistical Dispute at the Center of the Vote
The evidence rests largely on a single trial called HOPE-3. It was randomized, double-blind and placebo-controlled, ran 12 months, and enrolled 106 males aged 10 to 22 across multiple sites. Fifty-four received deramiocel and 52 received placebo. About 85 percent were non-ambulatory, the average age was roughly 15, and average heart pumping function at the start was within the normal range.
The FDA's written review was direct. The briefing document stated that "the study did not meet its pre-specified primary and secondary efficacy endpoints."
The dispute centers on how the heart measure was analyzed. The company's original plan was to examine change in left ventricular ejection fraction, a measure of how well the heart pumps. Capricor changed to a ranked analysis using a different statistical test the day before the data were unblinded. Even after that change, the result carried a p-value of 0.09, which does not meet the conventional threshold for statistical significance.
Capricor chief executive Linda Marbán disputed the agency's characterization of events, telling the committee that on first reading the briefing document, "parts of it were so hard to reconcile with what actually occurred."
Readers should weigh two limitations here rather than at the end. This is one trial of 106 participants in a rare disease, which is a small evidence base by design and not by carelessness. And ejection fraction is a measure of heart function rather than a direct measure of survival or hospitalization, so even a clear result would leave open how much difference patients would feel.
What Families Can Reasonably Do Now
The reasonable action is to keep existing cardiac care unchanged and to raise questions at the next scheduled appointment rather than seeking an urgent visit. Standard Duchenne cardiac management, including the heart medications a cardiologist already prescribes, is unaffected by this vote.
Families interested in the therapy should ask their neuromuscular team whether the child would even have fit the trial population, since HOPE-3 enrolled a specific age range and a largely non-ambulatory group. That answer is often more useful than the regulatory news itself.
No one should stop, start, or adjust a prescribed heart medication based on a news report. Treatment changes in Duchenne cardiomyopathy belong to the treating cardiologist and neuromuscular specialist.
Households facing cost questions can ask their care center's social worker about the patient assistance and travel support programs that many neuromuscular clinics coordinate, which operate independently of this application.
Two things remain unknown. The FDA has not announced its decision, and the agency has not said publicly whether it will follow the panel. What is confirmed is the vote, the margin, and the deadline. The most affected group is families of older, non-ambulatory boys with documented cardiac involvement. The central uncertainty is whether the agency treats a single small trial in a rare disease with the flexibility that advocates requested. The next expected development is the FDA decision on or before August 22.
Frequently Asked Questions
What exactly did the advisers vote on? Whether evidence from the HOPE-3 trial provides substantial evidence that deramiocel is effective for cardiomyopathy in Duchenne muscular dystrophy. The panel voted 9 to 3 that it does not.
Does this mean the FDA has rejected the therapy? No. The vote is a non-binding recommendation. The FDA conducts its own review and is expected to decide by August 22, 2026.
Is any therapy approved for the heart disease in Duchenne right now? No therapy is currently approved specifically for Duchenne cardiomyopathy. Cardiologists manage it with standard heart failure medications.
Should we change our son's treatment because of this vote? No. Nothing about current cardiac care changes. Discuss any questions at the next scheduled appointment, and do not adjust medications without the treating clinician.
What is happening on August 4? Duchenne advocacy organizations have scheduled a community town hall at 1 p.m. Eastern on what follows an advisory committee hearing. It is an information session, not a regulatory announcement.
Why is a p-value of 0.09 a problem? By convention, results are considered statistically significant below 0.05. A value of 0.09 means the finding could plausibly reflect chance, which is why reviewers questioned it.
What happens if the FDA declines to approve it? The company could pursue additional data or another submission. Families would continue with existing standard cardiac care in the meantime.
